Inogen, Inc (NASDAQ:INGN - Get Free Report)'s share price passed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $6.26 and traded as low as $5.05. Inogen shares last traded at $5.09, with a volume of 530,331 shares.
Analyst Ratings Changes
Separately, Weiss Ratings reissued a "sell (d-)" rating on shares of Inogen in a research report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy".
Check Out Our Latest Stock Analysis on Inogen
Inogen Price Performance
The business's fifty day simple moving average is $5.79 and its 200 day simple moving average is $6.26. The stock has a market cap of $135.09 million, a price-to-earnings ratio of -5.66 and a beta of 1.57.
Inogen (NASDAQ:INGN - Get Free Report) last issued its earnings results on Thursday, August 6th. The medical technology company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.15) by $0.01. Inogen had a negative net margin of 6.94% and a negative return on equity of 13.17%. The firm had revenue of $95.08 million for the quarter, compared to analysts' expectations of $95.23 million.
Insider Activity
In other news, EVP Jennifer Yi Boyer sold 10,938 shares of the business's stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $6.60, for a total transaction of $72,190.80. Following the completion of the transaction, the executive vice president owned 5,039 shares of the company's stock, valued at approximately $33,257.40. The trade was a 68.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 2.50% of the company's stock.
Hedge Funds Weigh In On Inogen
Hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. acquired a new stake in Inogen in the second quarter worth about $11,281,000. Armistice Capital LLC increased its holdings in shares of Inogen by 46.3% in the fourth quarter. Armistice Capital LLC now owns 1,264,000 shares of the medical technology company's stock valued at $8,494,000 after buying an additional 400,000 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in shares of Inogen by 203.9% in the first quarter. Arrowstreet Capital Limited Partnership now owns 586,159 shares of the medical technology company's stock valued at $3,622,000 after buying an additional 393,310 shares in the last quarter. Moore Capital Management LP lifted its position in shares of Inogen by 3.3% during the 2nd quarter. Moore Capital Management LP now owns 289,128 shares of the medical technology company's stock valued at $1,865,000 after acquiring an additional 9,229 shares during the last quarter. Finally, Readystate Asset Management LP acquired a new stake in shares of Inogen during the 2nd quarter valued at $1,718,000. 89.94% of the stock is currently owned by institutional investors and hedge funds.
About Inogen
(
Get Free Report)
Inogen, Inc is a medical technology company that develops, manufactures and distributes oxygen therapy products for people with chronic respiratory conditions. Its offerings are designed to provide supplemental oxygen outside traditional clinical settings, including at home and while traveling.
The company is best known for its Inogen One family of portable oxygen concentrators, which extract oxygen from ambient air and deliver it to patients without requiring refillable oxygen tanks. Inogen also offers stationary oxygen concentrators, accessories and related services, including equipment support and rental programs.
Founded in 2001 and headquartered in Goleta, California, Inogen serves customers through direct-to-consumer sales, health care providers and distributors.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Inogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inogen wasn't on the list.
While Inogen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
